Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): KSI-301

            Therapeutic Area: Ophthalmology Product Name: KSI-301

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Kodiak Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 27, 2020

            Details:

            Purpose-built bioconjugation facility in Lonza’s Ibex™ Dedicate Biopark to support the potential commercial launch of Kodiak's leading ophthalmic therapeutic candidate KSI-301 with a capacity to supply millions of doses per year.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sepofarsen

            Therapeutic Area: Ophthalmology Product Name: QR-110

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 02, 2021

            Details:

            ProQR’s is going to present abstract titled "A different type of genetic therapy: correcting a defective gene using antisense oligonucleotide treatment in CEP290 p.Cys998X LCA".

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KSI-301

            Therapeutic Area: Ophthalmology Product Name: KSI-301

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            Details:

            Kodiak Sciences has concluded recruitment in its DAZZLE pivotal study of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with neovascular (wet) age-related macular degeneration. Over 550 patients enrolled worldwide.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Voclosporin

            Therapeutic Area: Ophthalmology Product Name: ISA247

            Highest Development Status: Phase II/ Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            Details:

            Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES) did not achieve statistical significance on the primary endpoint of ≥ 10mm improvement in Schirmer Tear Test (STT) at 4 weeks.